BACKGROUND AND PURPOSE: Positron emission tomography (PET) with @entity9241 ( @entity9241 ) provides a non-invasive assessment of @entity519 . The aim of this study is to assess the feasibility of a dose escalation with volumetric modulated arc therapy (VMAT) guided by @entity9241 -PET for @entity135 ( @entity135 ). @entity1 AND METHODS: Ten @entity1 with inoperable stages III-IV @entity135 underwent @entity9241 -PET before radiotherapy. @entity519 target volumes (HTV) were segmented automatically by using the fuzzy locally adaptive Bayesian method. Retrospectively, two VMAT plans were generated delivering 70  Gy to the gross @entity5 volume (GTV) defined on computed tomography simulation or 79.8  Gy to the HTV. A dosimetric comparison was performed, based on calculations of @entity5 ( @entity5 ), normal tissue complication probability (NTCP) for the parotid glands and uncomplicated @entity5 (UTCP). RESULTS: The mean @entity519 fraction, defined as the ratio between the HTV and the GTV, was 0.18. The mean average dose for both parotids was 22.7  Gy and 25.5  Gy without and with dose escalation respectively. FMISO-guided dose escalation led to a mean increase of @entity5 , NTCP for both parotids and UTCP by 18.1, 4.6 and 8   % respectively. CONCLUSION: A dose escalation up to 79.8  Gy guided by @entity9241 -PET with VMAT seems feasible with improvement of @entity5 and without excessive increase of NTCP for parotids.

XXXX imaging with @entity9241 -PET for guided dose escalation with intensity-modulated radiotherapy in @entity135 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity135 :: ('MESH:D006258', 'Disease') :: ['HNC', 'head-and-neck cancers'] @entity9241 :: ('MESH:C031843', 'Chemical') :: ['[(18)F]-FMISO', '[(18)F]-fluoromisonidazole'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour control probability', 'TCP', 'tumour'] @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxic', 'hypoxic', 'hypoxia']
@entity519 :: (MESH:D000860,Disease) :: ['Hypoxia']
